

Beaumont Laboratory

Clinical Pathology Royal Oak, MI Effective Date: Supersedes: 02/28/2019

Angiotensin Converting Enzyme on Abbott Architect

RC.CH.CSL.ARC.PR.04r00

Principle

The following reaction is catalyzed by ACE:

ACE FAPGG → FAP + Glycylglycine

FAPGG is hydrolyzed to furylacryloylphenylalanine (FAP) and glycylglycine. Hydrolysis of FAPGG results in a decrease in absorbance at 340 nm. The ACE activity in the sample is determined by comparing the sample reaction rate to that obtained with the ACE Calibrator

Clinical Significance

The angiotensin converting enzyme assay is used to aid in the diagnosis of active sarcoidosis. It may be useful for confirmation of Gaucher's disease.

Specimen Collection and Handling

Serum collected in an SST tube. Refrigerate within 2 hours of collection. Sample is stable for 1 week refrigerated at 2° – 8° C and several months frozen.

Reagents

Trinity Biotech Ace lyophilized Reagent 10mL, 305-10. Reagent is prepared by adding 10mL of reagent grade deionized water. Stopper and mix several times by inversion. Reagent is stable for 30 days at $2^{\circ} - 8^{\circ}$ C once reconstituted. Transfer reagent to a 20mL Architect reagent cartridge.

Calibration

Trinity Biotech ACE Calibrator, 30550. Prepare by adding 1.0mL reagent grade deionized water to vial. Swirl gently and stand for 5 minutes. Invert gently and mix well to dissolve. Swirl gently to mix before each use. Calibration is performed with each run. Calibrator is stable for 7 days at $2^{\circ} - 8^{\circ}$ C once reconstituted.

Quality Control

ACE Control-N, 6040 and ACE Control-E, 7040. Prepare by adding 1.0mL reagent grade deionized water to vial. Swirl gently and stand for 5 minutes. Invert gently and mix well to dissolve. Swirl gently before each use. Control is stable for 7 days at $2^{\circ} - 8^{\circ}$ C once reconstituted.

Refer to QC Procedures and Policies for Automated Chemistry for handling QC results that are outside of the expected values.

Special Safety Precautions

Follow Universal Precautions when handling specimens and quality control materials.

Procedure

- 1. ACE testing is performed on the Architect Chemistry Analyzer using user defined settings. System must be in ADMIN to open a new lot of reagent.
- 2. Select System at the top of the screen, Configuration, Assay Categories.
- 3. Select Reagent Settings, ACE, F-6 Configure.
- 4. The Configure reagent window displays.
- 5. Select the New Lot option under lot number. Enter the Lot Number, expiration and Serial Number. (Note: the serial number is required but can be any number)
- 6. Define the cartridge sizes for R1. Select Done.
- 7. Select the Reagents button at the top of the screen. Select F-6 Assign Location. Highlight the reagent and select the location. Select Done.
- 8. Packs of the same lot can be replaced in the same location as the onboard pack by selecting Reagents, Highlighting the Reagent Pack and Selecting F-8 Reset.
- 9. Samples should be well mixed before testing. Testing is performed on Tuesday and Friday 6:30 to 15:00.

Calculations and Interpretations

Completed results will automatically upload to Instrument Manager. Results needing operator attention will remain in Held Status in Instrument Manager for further investigation.

Expected Values

8-52 U/L

Reportable Range

This method is linear from 1-120 U/L

Interfering Substances

ACE is inhibited by EDTA and by ACE inhibitors (eg. Captopril, Vasotec) used in the treatment of hypertension.

References

Trinity Biotech ACE IFU

Authorized Reviewers

Section Medical or Technical Director

Printed copies of this document are not considered up-to-date. Please verify current version date with online document.

Document Control

Location of Master: Master electronic file stored on the Beaumont Laboratory server under S: /AutoChem/DocCont/CSL/ARC

Master printed document stored in the Abbott Architect Chemistry Procedure Manual Core Lab Number of Controlled Copies posted for educational purposes: 0 Number of circulating Controlled Copies: 0 Location of circulating Controlled Copies: NA

Document History

Signature Prepared by: R Carey-Ballough MT(ASCP)	Date 02-28-2019	Revision #		Related Documents Reviewed/ Updated
Approved by: Kenneth Simkowski, PhD	3/19/2019			
Reviewed by: (Signature)	Date	Revision #	Modification	Related Documents Reviewed/ Updated
Peter Millward, MD	3/21/2019	r00		

Printed copies of this document are not considered up-to-date. Please verify current version date with online document.